Short News

Print

short news

Prof. Tahir Saeed Haroon
passes away

LAHORE: Prof. Tahir Saeed Haroon an eminent dermatologist who retired as Professor and Head of the Dept. of Dermatology from King Edward Medical College many years ago who is known as Father of Dermatology in Pakistan passed away on Saturday night January 6, 2018. May God Almighty rest the departed soul in eternal Peace. Ameen. He leaves behind a large number of friends and well-wishers besides family members to mourn his death.


Prof. Tahir Saeed Haroon

Late Prof. Tahir Saeed Haroon was invited to be the Chief Guest at the recently held SAARC Conference of Dermatology organized by Pakistan Association of Dermatologists at Lahore from November 17-19th 2017 which was his last function. It looks as if that was his Farewell by the dermatologist’s community. Despite the fact that he was not keeping good health for the last many months, he came to the meeting and also attended the Conference Dinner which provided an opportunity to a large number of his students to meet him. Members of Pakistan Association of Medical Editors (PAME) have also condoled his death. Detailed obituary note will be published later-Chief Editor


Pakistan Live 2018 from
29-31st March, 2018 at Islamabad

ISLAMABAD: Pakistan Society of Interventional Cardiology will organize its Third Pakistan Live 2018, from 29- 31st March, 2018 at Islamabad. For details contact PSIC Secretariat: Cardiology Department, Shaikh Zayed Hospital, Lahore. Tel: (+92-42)35865731-35 Ext. 2804-2808 E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. Website: www.psic.com.pk


Diabetes Foot Care Services may
help avoid Lower Limb Amputations

In a Diabetic Medicine study that compared different regions in England, areas that provided 10 key services for diabetes foot care had lower rates of major diabetes-related lower limb amputations.

Services introduced included administrative support, standardized general practice foot screening, and improved community podiatry staffing, hospital multidisciplinary foot clinics, effective care pathways, availability of an orthotist and audit. Based on these findings we strongly recommend robust commissioning to provide and coordinate 10 key service provisions for diabetic foot care, wrote the authors of the study.


Analysis provides reassurance
on the safety of Biosimilars

Biosimilars have been available in the European Union since 2006. A new British Journal of Clinical Pharmacology analysis of publicly available regulatory documents found no substantial differences in the reporting of safety information for biosimilars and related originators.

The analysis included 19 biosimilars and 6 originators. Overall, 55 general safety concerns (12 low, 21 medium, and 22 highly clinically relevant) were identified. For all substances, except for infliximab, no or only one difference was found in the listed general safety concerns. Comparison of regulatory documents for infliximab identified 3 medium clinically relevant general safety concerns more for infliximab biosimilars and 2 general safety concerns more for its originator.

© Professional Medical Publications. All rights reserved.